XTalks

NOVEMBER 1, 2024

The neurology drug market continues to be dynamic with novel treatments that cater to a broad range of neurological and psychiatric conditions. In this blog, we highlight the top 20 best-selling neurology drugs to watch in 2024, based on 2023 sales statistics.

FDA Approval 85

FDA Approval Drugs Botox Sales 85

XTalks

JANUARY 20, 2025

Key benefits included the addition of Celgenes blockbuster drug Revlimid (lenalidomide), a cornerstone of its oncology portfolio, and access to innovative CAR-T therapies such as Abecma (idecabtagene vicleucel). While the deal required regulatory divestitures, including the sale of Otezla (apremilast) to Amgen for $13.4

Marketing 104

Marketing Botox Life Science Pharma Companies 104

pharmaphorum

NOVEMBER 4, 2020

The HER-MES trial found that Aimovig (erenumab) was more effective at preventing migraine attacks and also better tolerated than topiramate, a generic epilepsy drug which is known to have side effects like sleepiness, dizziness, diarrhoea and nausea. Novartis and Amgen are however locked in a legal battle over marketing rights to the drug.

Botox 96

Botox Sales Doctor Doctors 96

pharmaphorum

NOVEMBER 18, 2020

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone. Aimovig is said to be the most prescribed anti-CGRP drug worldwide with more than 480,000 patients prescribed the drug worldwide.

Sales 96

Sales Botox Antibody Drugs 96

pharmaphorum

NOVEMBER 18, 2020

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone. Aimovig is said to be the most prescribed anti-CGRP drug worldwide with more than 480,000 patients prescribed the drug worldwide.

Sales 94

Sales Botox Antibody Drugs 94

XTalks

JULY 4, 2024

The pharma industry is poised for significant transformations in 2024, driven by groundbreaking drugs that have set new benchmarks in the industry. This blog delves into the top 30 drugs to watch in 2024, leveraging insights from their sales performance in 2023. billion DKK ($21.1 billion USD).

Sales 40

Sales Drugs FDA Approval Marketing 40

pharmaphorum

SEPTEMBER 29, 2021

AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Qulipta – its once-daily oral preventive therapy for episodic migraines. AbbVie acquired Qulipta in 2020 as part of its $63 billion takeover of Allergan, which also brought in Botox and Ubrelvy.

Botox 52

Botox Sales Marketing FDA Approval 52